Most Recent
Target has lodged an appeal after an IP Australia delegate rejected its opposition to a e-commerce merchandise importer's bid to register a diagonal arrow as a trade mark.
The High Court of New Zealand has refused to grant New Zealand Rugby an interim injunction preventing the Australian Rugby League Commission from using the names 'PNG Chiefs' or 'Chiefs' in New Zealand.
Kmart is fighting a fintech's application to register a trade mark featuring a chevron shape and the letter 'k', arguing the application was made in bad faith.
Swedish IP services group Abion has purchased Brandsec's corporate domain management business, as it targets further growth across the Asia-Pacific region.
AstraZeneca has denied claims by Pharmacor that a patent for its diabetes drug Forxiga is invalid and that an extension of the patent's term was wrongly granted.
Adelaide-based Mayne Pharma Group has settled its dispute with generic drug maker Teva Pharmaceuticals over patents covering hormone replacement drug IMVEXXY.
Animal health giant Abbey Laboratories has fought off a challenge to its bid to register 'Virkill' as a trade mark for its disinfectant products, despite an IP Australia delegate finding the name was deceptively similar to its opponent's 'Virukill' mark.
Hugo Boss AG has successfully opposed an application to trade mark 'Mafiaboss' for clothing, footwear and leather goods, with a delegate finding the addition of 'mafia' was not enough to distinguish the trade marks.
Snapchat is gearing up for a fight with Australian print franchise Snap over its plans to register 'Snapchat Ads' as a trade mark.
Australian biotech CSL has inked an agreement with Swiss company Alentis Therapeutics to develop and commercialise an experimental antibody treatment for rare kidney and liver diseases in a deal worth up to $2.24 billion.